What You Should Know:
– Proscia®, a global leader in AI-enabled pathology solutions for precision medicine, has introduced the next version of Concentriq® AP.
– The release includes new functionality that advances the impact of AI in shaping pathologists’ understanding of four of the top five most common cancers worldwide. Concentriq AP is a cloud-based workflow solution that helps even the largest global laboratory networks achieve the confidence and efficiency gains enabled by digital pathology.
Proscia Advances Digital Pathology with Multi-AI Workflows and Enhanced Concentriq Platform
Proscia, a software company revolutionizing digital pathology, is accelerating the transformation of disease research and diagnosis, including cancer. Its Concentriq enterprise pathology platform, combined with powerful AI applications, is advancing the 150-year-old standard towards a data-driven discipline. This shift unlocks new insights, accelerates R&D, improves patient outcomes, and fulfills the promise of precision medicine. Proscia’s software is trusted daily by leading diagnostic laboratories and 14 of the top 20 pharmaceutical companies.
The latest update introduces the industry’s first multi-AI workflows, allowing simultaneous display of results from multiple applications within Proscia’s precision medicine AI portfolio on a single image. This innovation provides pathologists with a comprehensive view, moving beyond isolated analysis of individual solutions. Applications for breast, colon, gastric, lung, and prostate images are immediately available, with plans to expand to additional tissue types and use cases, incorporating other leading third-party solutions.
“Proscia is ushering in a new era of AI in pathology,” said Derek C. Welch, M.D., Chief Medical Officer and Executive Vice-President at PathGroup. “As AI continues to demonstrate benefits, laboratories are increasingly seeking to leverage a variety of applications. Concentriq AP now enables them to realize the collective value of a broad AI portfolio while providing a robust solution for their routine operations.”
Additional features and functionality in the new release of Concentriq AP include:
– The ability to view and ingest DICOM images, paving the way for IT efficiencies and enhanced interoperability.
– API updates facilitating seamless integration of third-party and customer-built AI applications into Concentriq AP’s multi-AI workflows.
– Full support for 13 languages, reflecting Proscia’s expanding global customer base.
– Performance, scalability, and usability enhancements optimizing Concentriq AP for laboratories aiming for 100% digitization.
This announcement follows a series of significant developments from Proscia. The company recently published findings from a study with Quest Diagnostics on the impact of its AI-enabled workflows and announced a partnership with Nucleai to incorporate AI predictive biomarkers into its precision medicine AI portfolio. Additionally, Proscia has more than doubled its clinical customer base in the past year.
Proscia continues to lead the digital transformation in pathology, driving innovation and excellence in disease understanding and patient care.
